In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?
The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.
ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.
ADA 2019—Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.
Daily aspirin for primary prevention of heart disease is a practice under scrutiny. Based on the new 2019 ACC/AHA CVD prevention guidelines, is this patient a candidate?
Test your knowledge of the key elements and outcomes of the highly buzzed about REDUCE-IT trial with this 5-question quiz.
How much do you know about the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease? Take this 9-question quiz to find out.
Man's need for exercise began with foraging for subsistence and is just as essential in our age of sitting and screen time. Trace the evolution, here.
Eighty percent of all cardiovascular events are preventable. The ACC/AHA 2019 guidelines are a single source of best practices to help achieve that goal. Review them here, at-a-glance.
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.